DPPA4

Summary

DPPA4 (developmental pluripotency associated 4, HGNC:19200) is a protein-coding gene on chromosome 3q13.13, encoding Developmental pluripotency-associated protein 4 (Q7L190). May be involved in the maintenance of active epigenetic status of target genes.

This gene encodes a nuclear factor that is involved in the maintenance of pluripotency in stem cells and essential for embryogenesis. The encoded protein has a scaffold-attachment factor A/B, acinus and PIAS (SAP) domain that binds DNA and is thought to modify chromatin. Mice with a homozygous knockout of the orthologous gene die during late embryonic development or within hours after birth. Knockout embryos are normal in size at embryonic day 18.5 but exhibit skeletal and lung tissue abnormalities. This gene, when mutated, is highly expressed in embryonal carcinomas, pluripotent germ cell tumors, and other cancers and is thought to play an important role in tumor progression. Multiple pseudogenes of this gene have been identified. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 55211 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 26 total
• MANE Select transcript: NM_018189

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19200
Approved symbol	DPPA4
Name	developmental pluripotency associated 4
Location	3q13.13
Locus type	gene with protein product
Status	Approved
Aliases	FLJ10713
Ensembl gene	ENSG00000121570
Ensembl biotype	protein_coding
OMIM	614125
Entrez	55211

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 7 protein_coding, 3 retained_intron, 2 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000335658, ENST00000463966, ENST00000475135, ENST00000477303, ENST00000478791, ENST00000487299, ENST00000489281, ENST00000495679, ENST00000936552, ENST00000936553, ENST00000936554, ENST00000936555, ENST00000936556

RefSeq mRNA: 3 — MANE Select: NM_018189 NM_001348928, NM_001348929, NM_018189

CCDS: CCDS33814

Canonical transcript exons

ENST00000335658 — 7 exons

Exon	Start	End
ENSE00001338478	109326144	109328024
ENSE00001338483	109337464	109337546
ENSE00003507744	109333870	109333993
ENSE00003533320	109331871	109332031
ENSE00003543988	109330524	109330812
ENSE00003689009	109328890	109329088
ENSE00003693234	109331734	109331784

Expression profiles

Bgee: expression breadth ubiquitous, 150 present calls, max score 89.00.

FANTOM5 (CAGE): breadth broad, TPM avg 16.5179 / max 971.3744, expressed in 280 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
43700	14.8029	268
43701	1.1047	188
43702	0.3523	59
43698	0.1917	70
43697	0.0663	35

Top tissues by expression

272 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	89.00	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	86.91	gold quality
buccal mucosa cell	CL:0002336	84.54	gold quality
sural nerve	UBERON:0015488	70.95	gold quality
adrenal tissue	UBERON:0018303	70.79	gold quality
thymus	UBERON:0002370	68.53	silver quality
monocyte	CL:0000576	68.50	gold quality
leukocyte	CL:0000738	68.34	gold quality
mononuclear cell	CL:0000842	68.32	gold quality
testis	UBERON:0000473	67.90	gold quality
bone marrow	UBERON:0002371	65.86	gold quality
right testis	UBERON:0004534	65.78	gold quality
left testis	UBERON:0004533	64.50	gold quality
ventricular zone	UBERON:0003053	64.32	gold quality
bone marrow cell	CL:0002092	63.79	gold quality
placenta	UBERON:0001987	61.65	gold quality
ganglionic eminence	UBERON:0004023	59.59	gold quality
lymph node	UBERON:0000029	59.37	gold quality
granulocyte	CL:0000094	58.77	gold quality
adenohypophysis	UBERON:0002196	58.72	gold quality
embryo	UBERON:0000922	58.63	gold quality
right lobe of liver	UBERON:0001114	58.46	gold quality
stromal cell of endometrium	CL:0002255	56.72	gold quality
calcaneal tendon	UBERON:0003701	56.37	gold quality
pituitary gland	UBERON:0000007	56.19	gold quality
tendon of biceps brachii	UBERON:0008188	55.50	silver quality
hindlimb stylopod muscle	UBERON:0004252	54.95	gold quality
liver	UBERON:0002107	54.90	gold quality
gall bladder	UBERON:0002110	54.60	gold quality
cerebellar vermis	UBERON:0004720	54.47	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-MTAB-11121	yes	201.54
E-MTAB-9388	yes	14.63
E-ANND-3	yes	9.66
E-MTAB-7008	no	851.71
E-MTAB-5061	no	2.71

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): DLX5, EOMES, FOXC1, GATA6, HLX, ID2, NANOG, POU5F1, SOX2, TBX18, TBXT, ZFP42

miRNA regulators (miRDB)

70 targeting DPPA4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-6740-5P	100.00	65.64	932
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-539-3P	99.98	70.74	1616
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-3143	99.93	71.96	3104
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-3529-3P	99.90	73.55	3045
HSA-MIR-4496	99.88	68.89	2236
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-3133	99.81	70.92	3506
HSA-MIR-1825	99.72	68.11	1089
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-466	99.67	70.85	2863
HSA-MIR-3175	99.65	66.30	2031
HSA-MIR-4261	99.59	70.30	3415

Literature-anchored findings (GeneRIF, showing 9)

• Thsi study identifies DPPA4 and other genes as putative Sox2:Oct-3/4 target genes using a combination of in silico analysis and transcription-based assays. (PMID:18366076)
• Results identified a new family of pluripotency-related oncogenes consisting of DPPA2 and DPPA4. (PMID:23963736)
• knockdown of PCGF1 results in reduced expression of DPPA4 and other subunits of the variant PRC1 complex at both mRNA and protein levels (PMID:26687479)
• identifies EBP1 as a novel pluripotency cofactor and provides insight into potential mechanisms used by DPPA4 in regulating pluripotency through its association with EBP1 (PMID:29327467)
• Across cell types Dppa4 shows a preference for binding to regions with active chromatin signatures, and can influence chromatin modifications at target genes. Data provide novel insights into Dppa4 function in both pluripotent and oncogenic contexts. (PMID:30031967)
• Dppa4 promotes nonsmallcell lung cancer progression, partly through glycolysis by lactate dehydrogenase B. (PMID:31180527)
• Dppa2/4 as a trigger of signaling pathways to promote zygote genome activation by binding to CG-rich region. (PMID:33316032)
• Dynamic cytosolic foci of DPPA4 in human pluripotent stem cells. (PMID:36007377)
• Chromatin modifier developmental pluripotency associated factor 4 (DPPA4) is a candidate gene for alcohol-induced developmental disorders. (PMID:36581877)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Dppa4	ENSMUSG00000058550
rattus_norvegicus	Dppa4	ENSRNOG00000025404

Paralogs (1): DPPA2 (ENSG00000163530)

Protein

Protein identifiers

Developmental pluripotency-associated protein 4 — Q7L190 (reviewed: Q7L190)

All UniProt accessions (3): C9J7A7, Q7L190, F8WDC6

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in the maintenance of active epigenetic status of target genes. May inhibit differentiation of embryonic cells into a primitive ectoderm lineage.

Subunit / interactions. Interacts with DPPA2. Interacts with PCGF1.

Subcellular location. Nucleus.

RefSeq proteins (3): NP_001335857, NP_001335858, NP_060659* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR025891	Dppa2/4_C_dom	Domain
IPR025892	Dppa2/4_central_dom	Domain
IPR039590	Dppa2/4	Family

Pfam: PF14047, PF14049

UniProt features (10 total): modified residue 3, region of interest 2, compositionally biased region 2, sequence variant 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q7L190-F1	66.05	0.20

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 215, 221, 226

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-2892247	POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation
R-HSA-9819196	Zygotic genome activation (ZGA)

MSigDB gene sets: 81 (showing top): BENPORATH_NOS_TARGETS, RYTTCCTG_ETS2_B, GOBP_MESENCHYME_DEVELOPMENT, GOBP_RESPIRATORY_SYSTEM_DEVELOPMENT, JAATINEN_HEMATOPOIETIC_STEM_CELL_UP, CONRAD_STEM_CELL, RASHI_RESPONSE_TO_IONIZING_RADIATION_5, SHEN_SMARCA2_TARGETS_DN, GOMF_CHROMATIN_BINDING, BENPORATH_OCT4_TARGETS, ETS_Q4, CASORELLI_ACUTE_PROMYELOCYTIC_LEUKEMIA_DN, BENPORATH_ES_1, KORKOLA_EMBRYONAL_CARCINOMA, MIKKELSEN_ES_ICP_WITH_H3K4ME3

GO Biological Process (2): system development (GO:0048731), lung-associated mesenchyme development (GO:0060484)

GO Molecular Function (2): chromatin binding (GO:0003682), protein binding (GO:0005515)

GO Cellular Component (2): nucleus (GO:0005634), nucleoplasm (GO:0005654)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Transcriptional regulation of pluripotent stem cells	1
Maternal to zygotic transition (MZT)	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	2
multicellular organism development	1
anatomical structure development	1
lung development	1
mesenchyme development	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1124 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DPPA4	GDF3	Q9NR23	672
DPPA4	NANOG	Q9H9S0	663
DPPA4	POU5F1	P31359	636
DPPA4	UTF1	Q5T230	632
DPPA4	ZFP42	Q96MM3	626
DPPA4	DPPA3	Q6W0C5	611
DPPA4	SALL4	Q9UJQ4	605
DPPA4	SOX2	P48431	603
DPPA4	DPPA5	A6NC42	603
DPPA4	LIN28A	Q9H9Z2	590
DPPA4	ZSCAN4	Q8NAM6	571
DPPA4	ESRRB	O95718	570
DPPA4	CRIPTO	P13385	546
DPPA4	PRDM14	Q9GZV8	540
DPPA4	H3-3A	P06351	508

IntAct

116 interactions, top by confidence:

A	B	Type	Score
MMS19	CIAO1	psi-mi:“MI:0914”(association)	0.910
DPPA4	SH3GL1	psi-mi:“MI:0915”(physical association)	0.900
SH3GL1	DPPA4	psi-mi:“MI:0915”(physical association)	0.900
DPPA4	LDOC1	psi-mi:“MI:0915”(physical association)	0.780
LDOC1	DPPA4	psi-mi:“MI:0915”(physical association)	0.780
CRK	DPPA4	psi-mi:“MI:0915”(physical association)	0.670
PSH1	DPPA4	psi-mi:“MI:0915”(physical association)	0.610
DPPA4	PSH1	psi-mi:“MI:0915”(physical association)	0.610
DPPA4	GRB2	psi-mi:“MI:0915”(physical association)	0.560
DPPA4	EIF4A2	psi-mi:“MI:0915”(physical association)	0.560
DPPA4	SH3GL1	psi-mi:“MI:0915”(physical association)	0.560
RPGRIP1	DPPA4	psi-mi:“MI:0915”(physical association)	0.560
GRB2	DPPA4	psi-mi:“MI:0915”(physical association)	0.560
EIF4A2	DPPA4	psi-mi:“MI:0915”(physical association)	0.560
DPPA4	RPGRIP1	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (185): DPPA4 (Two-hybrid), DPPA4 (Two-hybrid), DPPA4 (Two-hybrid), DPPA4 (Two-hybrid), RPGRIP1 (Two-hybrid), ADD2 (Affinity Capture-MS), ADD1 (Affinity Capture-MS), HAL (Affinity Capture-MS), TGM1 (Affinity Capture-MS), SNX9 (Affinity Capture-MS), SH3GL1 (Affinity Capture-MS), L3MBTL3 (Affinity Capture-MS), CLU (Affinity Capture-MS), APOD (Affinity Capture-MS), SDR9C7 (Affinity Capture-MS)

ESM2 similar proteins: A2A3V1, A2A995, A5D7J3, B1AX39, O15446, O60303, O88573, P0DPK0, P23497, Q14684, Q1ED39, Q2KIN0, Q3KRF1, Q3TFK5, Q3UY34, Q4R2Z8, Q566R3, Q58CQ0, Q5I034, Q5PQK4, Q5PQN4, Q5SU73, Q5XG69, Q66H19, Q66LM6, Q68A65, Q6IR42, Q6NTE8, Q6P1D7, Q6P9P0, Q76KJ5, Q7L190, Q80YR5, Q8BI29, Q8BVK9, Q8C0X0, Q8C753, Q8IY92, Q8IYF1, Q8K4R9

Diamond homologs: D3Z8Y2, Q7L190, Q7Z7J5, Q8CCG4, Q9CWH0

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
POU5F1	“up-regulates quantity by expression”	DPPA4	“transcriptional regulation”
SOX2/POU5F1	“up-regulates quantity by expression”	DPPA4	“transcriptional regulation”
SOX17/POU5F1	“up-regulates quantity by expression”	DPPA4	“transcriptional regulation”

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 43 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Clathrin-mediated endocytosis	5	14.2×	1e-03
Membrane Trafficking	6	7.4×	3e-03
Vesicle-mediated transport	6	7.0×	4e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

26 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	23
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

892 predictions. Top by Δscore:

Variant	Effect	Δscore
3:109331785:C:CC	acceptor_gain	1.0000
3:109331888:G:C	donor_gain	1.0000
3:109332030:CA:C	acceptor_gain	1.0000
3:109332032:C:CC	acceptor_gain	1.0000
3:109332038:C:CT	acceptor_gain	1.0000
3:109332039:A:T	acceptor_gain	1.0000
3:109333990:TCCA:T	acceptor_gain	1.0000
3:109333991:CCA:C	acceptor_gain	1.0000
3:109333991:CCAC:C	acceptor_gain	1.0000
3:109333992:CA:C	acceptor_gain	1.0000
3:109333992:CAC:C	acceptor_gain	1.0000
3:109333994:C:CC	acceptor_gain	1.0000
3:109337462:ACCT:A	donor_gain	1.0000
3:109337463:CCTC:C	donor_gain	1.0000
3:109337465:T:TA	donor_gain	1.0000
3:109330518:GCTTA:G	donor_loss	0.9900
3:109330519:CTTA:C	donor_loss	0.9900
3:109330520:TTACC:T	donor_loss	0.9900
3:109330521:TACC:T	donor_loss	0.9900
3:109330522:A:C	donor_loss	0.9900
3:109330523:C:CA	donor_loss	0.9900
3:109330811:TC:T	acceptor_gain	0.9900
3:109330811:TCCTA:T	acceptor_loss	0.9900
3:109330812:CC:C	acceptor_gain	0.9900
3:109330814:T:C	acceptor_loss	0.9900
3:109331782:TTT:T	acceptor_gain	0.9900
3:109331783:TTCT:T	acceptor_loss	0.9900
3:109331784:TCTAA:T	acceptor_loss	0.9900
3:109331785:CTA:C	acceptor_loss	0.9900
3:109331786:T:C	acceptor_loss	0.9900

AlphaMissense

1974 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:109328911:A:G	L286S	0.999
3:109328909:A:G	C287R	0.998
3:109329080:A:G	W230R	0.998
3:109329080:A:T	W230R	0.998
3:109331906:A:G	W102R	0.998
3:109331906:A:T	W102R	0.998
3:109328911:A:C	L286W	0.997
3:109329002:A:G	W256R	0.997
3:109329002:A:T	W256R	0.997
3:109328900:A:G	C290R	0.996
3:109329064:C:A	G235V	0.996
3:109328921:C:G	D283H	0.995
3:109329000:C:A	W256C	0.995
3:109329000:C:G	W256C	0.995
3:109329035:A:G	W245R	0.995
3:109329035:A:T	W245R	0.995
3:109329065:C:A	G235W	0.995
3:109329070:A:T	V233D	0.995
3:109329078:C:A	W230C	0.995
3:109329078:C:G	W230C	0.995
3:109331772:A:C	Y118D	0.995
3:109331904:C:A	W102C	0.995
3:109331904:C:G	W102C	0.995
3:109328907:G:C	C287W	0.994
3:109328920:T:A	D283V	0.994
3:109331901:G:C	C103W	0.994
3:109328021:G:C	N294K	0.993
3:109328021:G:T	N294K	0.993
3:109328899:C:G	C290S	0.993
3:109328900:A:T	C290S	0.993

dbSNP variants (sampled 300 via entrez): RS1000008328 (3:109337546 T>C,G), RS1000061277 (3:109334647 G>A), RS1000439897 (3:109328880 A>G), RS1001133949 (3:109326923 T>C), RS1001240269 (3:109334375 C>T), RS1001445453 (3:109340152 G>T), RS1001471912 (3:109333736 G>A,C,T), RS1002411083 (3:109335955 C>G), RS1002738522 (3:109335407 C>A,G,T), RS1002853705 (3:109327259 A>G), RS1003078366 (3:109333377 A>C), RS1003183774 (3:109328467 C>T), RS1003816758 (3:109332430 C>T), RS1003823046 (3:109334676 A>C), RS1003932709 (3:109326833 G>A)

Disease associations

OMIM: gene MIM:614125 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST000960_5	Cardiac hypertrophy	3.000000e-06
GCST002064_7	Corneal astigmatism	2.000000e-06
GCST009391_1785	Metabolite levels	3.000000e-06

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0002503	cardiac hypertrophy
EFO:0004468	glucose measurement
EFO:0010477	fructose measurement
EFO:0010481	galactose measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

14 total (human), top 14 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, affects expression	5
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	decreases expression, affects cotreatment	2
Phenylmercuric Acetate	decreases expression, affects cotreatment	2
methylmercuric chloride	decreases expression	1
bisphenol A	decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
LDN 193189	affects cotreatment, decreases expression	1
(+)-JQ1 compound	decreases expression	1
Benzo(a)pyrene	affects methylation	1
Butyrates	increases expression	1
Carbamazepine	affects expression	1
Diethylhexyl Phthalate	decreases expression, increases expression	1
Lead	affects expression	1
Tretinoin	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer